Federal Register / Vol. 62, No. 7 / Friday, January 10, 1997 / Notices 1459

452–3204. You may call (202) 452–3207,

beginning at approximately 5 p.m. two

business days before this meeting, for a

recorded announcement of bank and bank

holding company applications scheduled for

the meeting.

Dated: January 8, 1997.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 97–720 Filed 1–8–97; 10:32 am]

BILLING CODE 6210–01–P

FEDERAL TRADE COMMISSION

[File No. 961–0056]

Phillips Petroleum Company; Analysis

to Aid Public Comment

AGENCY: Federal Trade Commission.

ACTION: Proposed consent agreement.

SUMMARY: In settlement of alleged

violations of federal law prohibiting

unfair or deceptive acts or practices and

unfair methods of competition, this

consent agreement, accepted subject to

final Commission approval, would

require, among other things, the

Bartlesville, Oklahoma based company

to divest approximately 160 miles of its

natural gas pipeline system in

Oklahoma. The agreement settles

allegations that Phillips’ acquisition of

gas-gathering assets from ANR Pipeline

Company would substantially reduce

competition for natural gas gathering

services in areas of five Oklahoma

counties, because Phillips and ANR are

the only, or two of very few, companies

that provide gas gathering services in

these areas. The Commission had

alleged that the acquisition could have

resulted in higher rates and reduced

drilling and production.

DATES: Comments must be received on

or before March 11, 1997.

ADDRESSES: Comments should be

directed to: FTC/Office of the Secretary,

Room 159, 6th St. and Pa. Ave., N.W.,

Washington, D.C. 20580.

FOR FURTHER INFORMATION CONTACT:

William J. Baer, Federal Trade

Commission, H–374, 6th St. and Pa.

Ave., N.W., Washington, D.C. 20580.

(202) 326–2932.

George S. Cary, Federal Trade

Commission, H–374, 6th St. and Pa.

Ave., N.W., Washington, D.C. 20580.

(202) 326–3741.

Phillip L. Broyles, Federal Trade

Commission, S–2105, 6th St. and Pa.

Ave., N.W., Washington, D.C. 20580.

(202) 326–2805.

SUPPLEMENTARY INFORMATION: Pursuant

to Section 6(f) of the Federal Trade

Commission Act, 38 Stat. 721, 15 U.S.C.

46, and Section 2.34 of the

Commission’s Rules of Practice (16 CFR

2.34), notice is hereby given that the

above-captioned consent agreement

containing a consent order to cease and

desist, having been filed with and

accepted, subject to final approval, by

the Commission, has been placed on the

public record for a period of sixty (60)

days. The following Analysis to Aid

Public Comment describes the terms of

the consent agreement, and the

allegations in the accompanying

complaint. An electronic copy of the

full text of the consent agreement

package can be obtained from the

Commission Actions section of the FTC

Home Page (for December 30, 1996), on

the World Wide Web, at ‘‘http://

www.ftc.gov/os/actions/htm.’’ A paper

copy can be obtained from the FTC

Public Reference Room, Room H–130,

Sixth Street and Pennsylvania Avenue,

N.W., Washington, D.C. 20580, either in

person or by calling (202) 326–3627.

Public comment is invited. Such

comments or views will be considered

by the Commission and will be available

for inspection and copying at its

principal office in accordance with

Section 4.9(b)(6)(ii) of the Commission’s

Rules of Practice (16 CFR 4.9(b)(6)(ii)).

Analysis to Aid Public Comment on the

Provisionally Accepted Consent Order

The Federal Trade Commission

(‘‘Commission’’) has accepted for public

comment from Phillips Petroleum Co.

(‘‘Phillips’’) an agreement containing

consent order. This agreement has been

placed on the public record for sixty

(60) days for reception of comments

from interested persons.

Comments received during this period

will become part of the public record.

After sixty (60) days, the Commission

will again review the agreement, the

comments received, and will decide

whether it should withdraw from the

agreement or make final the agreement’s

order.

The Commission’s investigation of

this matter concerns Phillips’ proposed

acquisition, through its wholly-owned

subsidiary, GPM Gas Services Corp., of

certain pipeline gathering systems

owned by ANR Pipeline Co. (‘‘ANR’’), a

subsidiary of Coastal Corporation.

Phillips and ANR are engaged in gas

gathering—the transportation of natural

gas, for their own or for others’ use,

from a wellhead or producing area to a

gas transmission pipeline or a gas

processing plant. The Commission’s

investigation of this matter found

potential anticompetitive problems in

certain areas within the following

Oklahoma counties: Beaver, Ellis,

Harper, Woods, and Woodward (‘‘the

Oklahoma counties’’). For certain gas

and oil producers in the Oklahoma

counties, Phillips and ANR are the only,

or two of very few, choices available to

provide gas gathering services. The

Commission was concerned that the

proposed merger would eliminate

competition between Phillips and ANR

in providing gas gathering services. The

Commission was also concerned that

the proposed merger would lead to

anticompetitive increases in gathering

rates to these producers, and an overall

reduction in gas drilling and

production.

The Agreement Containing Consent

Order would, if finally issued by the

Commission, settle charges alleged in

the Commission’s Complaint that

Phillips’ acquisition of ANR’s gas

gathering systems substantially lessened

competition in the gathering of natural

gas in the Oklahoma counties. The

nature of such competition to be

preserved is the actual and potential

competition to provide gas gathering

services to producers and other

customers. The Commission’s

Complaint further alleges that Phillips’

acquisition agreement with ANR

violates Section 7 of the Clayton Act

and Section 5 of the Federal Trade

Commission Act.

The order accepted for public

comment contains provisions that

would require Phillips to divest seven

parts of a pipeline system, consisting of

approximately 160 miles of pipe within

the Oklahoma counties. The gas

gathering assets to be divested are listed,

with accompanying maps showing the

locations of the pipelines, in Schedule

A of the proposed Consent Order.

Phillips must divest the assets by April

30, 1997 or 30 days following the

consummation of the acquisition,

whichever is later. The divestiture must

be made to a person approved by the

Commission and in a manner approved

by the Commission. The purposes of the

divestiture are to ensure the continued

use of the Schedule A assets in the same

type of business in which the assets are

used at the time of the acquisition, and

to remedy the lessening of competition

resulting from the acquisition.

If Phillips does not divest the assets

to a buyer acceptable to the Commission

by the deadline, the Commission may

appoint a trustee to sell the assets. The

trustee may include additional assets

with those specified in Schedule A to

assure the marketability, viability, and

competitiveness of the Schedule A

assets so as to accomplish expeditiously

the remedial purposes of the order.

For ten (10) years from the date that

the order becomes final, the order

would require prior Commission

notification before Phillips could
1460 Federal Register / Vol. 62, No. 7 / Friday, January 10, 1997 / Notices

acquire from any one person during any

18-month period more than five miles of

gas gathering pipelines located within

certain portions of the Oklahoma

counties.

In a separate agreement with Phillips,

the Commission expressed concern that

it might not have an adequate legal

remedy if the proposed acquisition were

consummated prior to Commission

action. Phillips has agreed to maintain

the assets that are being divested in

their current condition and provide

gathering service at existing terms and

conditions to customers under contract

with ANR until the Schedule A assets

are either sold or the Commission

decides not to accept this order.

The purpose of this analysis is to

invite public comment concerning the

consent order. This analysis is not

intended to constitute an official

interpretation of the agreement and

order or to modify their terms in any

way.

Donald S. Clark,

Secretary.

[FR Doc. 97–606 Filed 1–9–97; 8:45 am]

BILLING CODE 6750–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Agency for Health Care Policy and

Research

Notice of Meeting

In accordance with section 10(a) of

the Federal Advisory Committee Act (5

U.S.C., Appendix 2) announcement is

made of the following special emphasis

panel scheduled to meet during the

month of February 1997:

Name: Health Care Policy and Research

Special Emphasis Panel.

Date and Time: February 7, 1997, 8:00 a.m.

Place: Doubletree Hotel, 1750 Rockville

Pike, Halpine Room, Rockville, Maryland

20852.

Open February 7, 1997, 8:00 a.m. to 8:15

a.m. Closed for remainder of meeting.

Purpose: This Panel is charged with

conducting the initial review of grant

applications requesting dissertation support

for health services research undertaken as

part of an academic program to qualify for a

doctorate.

Agenda: The open session of the meeting

on February 7 from 8:00 a.m. to 8:15 a.m.,

will be devoted to a business meeting

covering administration matters. During the

closed session, the panel will be reviewing

and discussing grant applications dealing

with health services research issues. In

accordance with the Federal Advisory

Committee Act, section 10(d) of 5 U.S.C.,

Appendix 2 and 5 U.S.C., 552b(c)(6), the

Administrator, AHCPR, has made a formal

determination that this latter session will be

closed because the discussions are likely to

reveal personal information concerning

individuals associated with the grant

applications. This information is exempt

from mandatory disclosure.

Anyone wishing to obtain a roster of

members or other relevant information

should contact Carmen Johnson, Agency for

Health Care Policy and Research, Suite 400,

2101 East Jefferson Street, Rockville,

Maryland 20852, Telephone (301) 594–1449

x1613.

Agenda items for this meeting are subject

to change as priorities dictate.

Dated: January 3, 1997.

Clifton R. Gaus,

Administrator.

[FR Doc. 97–654 Filed 1–9–97; 8:45 am]

BILLING CODE 4160–90–M

Food and Drug Administration

[Docket No. 95N–0200]

Guidance for the Submission of

Chemistry, Manufacturing, and

Controls Information and

Establishment Description for

Autologous Somatic Cell Therapy

Products; Availability

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing the

availability of a guidance entitled

‘‘Guidance for the Submission of

Chemistry, Manufacturing, and Controls

Information and Establishment

Description for Autologous Somatic Cell

Therapy Products.’’ This guidance,

prepared by the Center for Biologics

Evaluation and Research (CBER) in

consultation with the Center for Devices

and Radiological Health, is intended to

assist applicants in the preparation of

the chemistry, manufacturing, and

controls (CMC) section and the

establishment description section of a

biologics license application (BLA) or in

the preparation of a product license

application (PLA) and establishment

license application (ELA) for all

autologous somatic cell therapy

products. This guidance may assist in

complying with certain requirements in

the Code of Federal Regulations.

DATES: Written comments may be

submitted at any time; however,

comments submitted by April 10, 1997,

will be considered for the next revision.

ADDRESSES: Submit written requests for

single copies of the guidance entitled,

‘‘Guidance for the Submission of

Chemistry, Manufacturing, and Controls

Information and Establishment

Description for Autologous Somatic Cell

Therapy Products’’ to the Office of

Communication, Training and

Manufacturers Assistance (HFM–40),

Center for Biologics Evaluation and

Research, Food and Drug

Administration, 1401 Rockville Pike,

Rockville, MD 20852–1448. Send one

self-addressed adhesive label to assist

that office in processing your requests.

The document may also be obtained by

mail or by calling the CBER Voice

Information System at 1–800–835–4709,

or 301–827–1800, or FAX at 1–800–

CBER–FAX, or 301–827–3844.

Persons with access to the Internet

may obtain the document in several

ways. Users of ‘‘Web Browser’’ software,

such as Mosaic, Netscape, or Microsoft

Internet Explorer may obtain this

document via the World Wide Web by

using the following Uniform Resource

Locators:

http://www.fda.gov/cber/cberftp.html

ftp://ftp.fda.gov/CBER/

The document may also be obtained

via File Transfer Protocol (FTP).

Requests should connect to the FDA’s

FTP Server,

FTP.FDA.GOV(192.73.61.21). CBER

documents are maintained in a

subdirectory called ‘‘CBER’’ on the

server. Logins with the user name of

anonymous are permitted, and the

user’s e-mail address should be sent as

the password. The ‘‘READ.ME’’ file in

that subdirectory describes the available

documents which may be available as

an ASCII text file (*.TXT), or a Word

Perfect 5.1 or 6.x document

(*.w51,wp6), or both. Finally, the

guidance can be obtained by ‘‘bounceback e-mail’’. A message should be sent

to: ‘‘XVCMC@al.cber.fda.gov’’.

Submit written comments on the

guidance to the Dockets Managements

Branch (HFA–305), Food and Drug

Administration, 12420 Parklawn Dr.,

rm. 1–23, Rockville, MD 20857. Two

copies of any comments are to be

submitted, except that individuals may

submit one copy. Requests and

comments should be identified with the

docket number found in brackets in the

heading of this document. A copy of the

guidance and received comments are

available for public examination in the

Dockets Management Branch between 9

a.m. and 4 p.m., Monday through

Friday.

FOR FURTHER INFORMATION CONTACT:

Sharon A. Carayiannis, Center for

Biologics Evaluation and Research

(HFM–630), Food and Drug

Administration, 1401 Rockville Pike,

Rockville, MD 20852–1448, 301–594–

3074.

SUPPLEMENTARY INFORMATION:

Over the last several years, FDA has

worked to clarify its approach to the